These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 18022724)

  • 21. Hepatic lipid metabolism and non-alcoholic fatty liver disease.
    Tessari P; Coracina A; Cosma A; Tiengo A
    Nutr Metab Cardiovasc Dis; 2009 May; 19(4):291-302. PubMed ID: 19359149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bile acid levels are increased in the liver of patients with steatohepatitis.
    Aranha MM; Cortez-Pinto H; Costa A; da Silva IB; Camilo ME; de Moura MC; Rodrigues CM
    Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):519-25. PubMed ID: 18467911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetes.
    Cho H; Um J; Lee JH; Kim WH; Kang WS; Kim SH; Ha HH; Kim YC; Ahn YK; Jung DW; Williams DR
    Sci Rep; 2017 Mar; 7():44186. PubMed ID: 28272459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
    Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
    Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis.
    Musso G; Gambino R; De Michieli F; Biroli G; Fagà E; Pagano G; Cassader M
    Ann Med; 2008; 40(5):383-94. PubMed ID: 18484349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH).
    Henriksen JH; Ring-Larsen H
    J Hepatol; 2008 Jan; 48(1):174-6. PubMed ID: 18022724
    [No Abstract]   [Full Text] [Related]  

  • 29. Commonly used animal models of non-alcoholic steatohepatitis.
    Fan JG; Qiao L
    Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):233-40. PubMed ID: 19502161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.